Core Insights - UroGen Pharma is experiencing early commercial momentum for its newly launched product Zusduri, particularly following the implementation of a permanent J-code that has improved patient access and engagement from urologists [3][6][10] Financial Performance - In 2025, UroGen reported total revenue of $109.8 million, an increase from $90.4 million in 2024, driven by the launch of Zusduri and growth in Jelmyto sales [5][16] - The company recorded a net loss of $153.5 million in 2025, compared to a net loss of $126.9 million in 2024, with cash and marketable securities totaling $120.5 million as of December 31, 2025 [5][18] Product Launch and Market Dynamics - Zusduri generated $15.8 million in revenue for 2025, with $1.8 million in net product revenue in Q3 and $14.0 million in Q4 [2][6] - By the end of 2025, there were 838 activated sites of care for Zusduri, with over 95% of covered lives having open access to the treatment [7][10] Clinical Outcomes and Feedback - The ENVISION trial supporting Zusduri's approval showed an approximately 80% complete response rate at three months, with a high probability of remaining event-free at 12 and 24 months [8] - Anecdotal feedback from physicians indicates that Zusduri integrates smoothly into practice, offering a non-surgical outpatient option that is valued by patients [9] Future Developments - UroGen plans to submit an NDA for UGN-103 in the second half of 2026, with potential approval in 2027, and aims to transition to UGN-103 quickly after obtaining a permanent J-code [11][13] - The company is also evaluating UGN-104 and UGN-501, with ongoing clinical trials and plans for future studies [14][15] Operational Strategy - The company is investing heavily in the commercialization of Zusduri, with a focus on building infrastructure that will support future products like UGN-103 [22] - UroGen's refinancing efforts have reduced the cost of capital and extended repayment timelines, providing added flexibility for future growth [19][22]

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [19] - Net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [5] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [7][17] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care for Zusduri, with 102 unique prescribers and 32 repeat prescribers [15] - Over 95% of covered lives had open access to Zusduri by year-end 2025, facilitating broader adoption [15] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5][7] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [8][12] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility, supporting ongoing initiatives [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early trajectory of Zusduri's launch, with key indicators showing acceleration in prescriber engagement and patient access following the implementation of a permanent J-code [5][15] - The company anticipates narrowing conversion timelines from patient enrollment to dosing as sites gain familiarity with the product [16] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects to offer guidance after gaining visibility into steady-state demand [29] - Operating expenses for 2026 are expected to be in the range of $240 million to $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they expect to provide formal guidance for Zusduri at least two quarters post the permanent J-code implementation [29] - There has been a noticeable increase in key indicators, including patient enrollment forms, since the J-code became effective [31][32] Question: Trends in repeat prescribers and feedback from new prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [38] - New prescribers are waiting for clean claim submissions and reimbursement confidence before becoming repeat prescribers [38] Question: Timing for UGN-103 market introduction and its relationship with Zusduri - UGN-103 is expected to be introduced after obtaining a permanent J-code, likely in early 2028 [40][41] Question: Current use patterns for Zusduri among patients - Zusduri is primarily used for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its efficacy [47] Question: Opportunities for Zusduri in the adjuvant setting - There is interest in exploring Zusduri in the adjuvant setting for high-risk disease, with ongoing protocol finalization for trials [59][60]

Financial Data and Key Metrics Changes - Revenues for the year ended December 31, 2025, were $109.8 million, a 21% increase from $90.4 million in 2024, driven by the commercial launch of Zusduri and increased sales of Jelmyto [18] - The net loss for 2025 was $153.5 million, or $3.19 per share, compared to a net loss of $126.9 million, or $2.96 per share in 2024 [21] - Cash equivalents and marketable securities totaled $120.5 million as of December 31, 2025 [21] Business Line Data and Key Metrics Changes - Zusduri generated $15.8 million in revenue for 2025, reflecting early launch dynamics [4] - Jelmyto generated net product revenue of $94 million for the full year 2025, indicating continued underlying demand growth [5][16] Market Data and Key Metrics Changes - As of December 31, 2025, there were 838 activated sites of care with 102 unique prescribers and 32 repeat prescribers for Zusduri [14] - Over 95% of covered lives had open access to Zusduri by year-end 2025 [14] Company Strategy and Development Direction - The primary focus is on the commercial launch of Zusduri, which addresses a large and underserved market, with potential peak revenue exceeding $1 billion [5] - The company is advancing its pipeline, including UGN-103 and UGN-104, with plans for NDA submissions and potential FDA approvals in 2026 and 2027 [6][11] - A refinancing agreement with Pharmakon Advisors has strengthened the balance sheet and enhanced financial flexibility [7][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early adoption of Zusduri, with positive feedback from prescribers and patients regarding its ease of use and clinical effectiveness [9][10] - The company anticipates that the conversion timeline from patient enrollment forms to dosing will improve as sites gain familiarity with the product [15] Other Important Information - The company is not providing formal sales guidance for Zusduri in 2026 due to its early launch stage but expects Jelmyto net product revenues to be in the range of $97 million to $101 million [23] - Full-year 2026 operating expenses are expected to be between $240 million and $250 million, driven by sales force expansion and lifecycle management plans [24] Q&A Session Summary Question: Insights on patient enrollment forms and potential guidance for Zusduri - Management indicated that they could consider providing formal guidance for Zusduri at least two quarters post the permanent J-code [28] - There has been a noticeable increase in key indicators since the J-code became effective, including new and repeat prescribers [30][31] Question: Trends in repeat prescribers and feedback from non-repeat prescribers - There is steady growth in both new and repeat prescribers, with positive experiences leading to increased confidence in reimbursement [36] Question: Lifecycle management and market introduction of UGN-103 - UGN-103 is expected to be introduced after obtaining a permanent J-code, with a potential launch in early 2028 [38] Question: Current use of Zusduri among different patient types - Zusduri is being used primarily for patients who recur early, have frequent recurrences, or are unfit for surgery, with enthusiasm from physicians regarding its clinical data [45][46] Question: Community versus academic center adoption of Zusduri - The utilization mix has shifted towards community settings, with approximately 50% of usage now in community practices [53][54]

Core Insights - The early 2025 revenue for Zasturi is projected at $15.8 million, attributed to a foundational launch phase aimed at establishing reimbursement pathways and operational readiness [1] - The activation of the permanent J code on January 1, 2026, is expected to be a key catalyst for increasing adoption rates among prescribers [1] - Early 2026 performance metrics for Zasturi indicate that patient enrollment forms and new starts have exceeded the historical performance of the company's first product, Jelmyto [1] Strategic Positioning - Zasturi is positioned as the only FDA-approved primary office-based therapy, aiming to disrupt the standard of care by providing a non-surgical alternative to TURBT procedures [1] - The company estimates a peak revenue potential of over $1 billion for Zasturi, based on high physician adoption and significant market penetration in the underserved NMIBC segment [1] Market Performance - Jelmyto is projected to generate $94 million in revenue for 2025, reflecting steady demand in a mature market [1] - The company plans to leverage the expanded Zasturi sales force to provide additional support to the Jelmyto franchise [1]

UroGen Pharma Conference Call Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Founded**: In Israel, addressing unmet needs in treating urothelial cancers - **Technology**: RTGel platform, a reverse thermal gel that allows sustained release of medications in the bladder [5][6] Core Products - **Commercial Assets**: - **Jelmyto**: Approved for low-grade upper tract urothelial carcinoma (6,000 patients in the U.S.) - **ZUSDURI**: Recently approved for low-grade intermediate-risk bladder cancer (60,000 patients in the U.S.) [7][8] Market Opportunity - **Patient Demographics**: - 60,000 newly diagnosed recurrent patients annually, with 68% having two or more recurrences [16] - 20,000 recurrent newly diagnosed patients, with a significant prevalent pool of low-grade intermediate-risk patients [16] - **Unmet Medical Need**: Historically, treatment was limited to surgical intervention (TURBT), leading to high recurrence rates [13][14] Product Launch and Performance - **ZUSDURI Launch**: - Initial revenue of $1.8 million, with October revenue reaching $4.5 million, indicating strong early performance [19] - Permanent J-code introduced in January, expected to accelerate uptake [36] - **Market Penetration**: - Estimated peak sales potential for ZUSDURI is over $1 billion, requiring only 20% market share to achieve this [37] Clinical Data and Feedback - **Efficacy**: - ZUSDURI demonstrated an 80% complete response rate, with 80% of those patients maintaining response at 12 months [25] - 90% of patients preferred ZUSDURI over TURBT based on patient-reported outcomes [25] - **Physician Feedback**: Positive reception from physicians, with many expressing enthusiasm for a non-surgical treatment option [22][25] Competitive Landscape - **Positioning**: UroGen believes ZUSDURI is the best treatment option due to its non-surgical nature and compelling clinical data [45] - **Market Growth**: The entry of additional treatments is seen as beneficial for overall market growth, with UroGen confident in its unique offering [44] Future Developments - **Next Generation Products**: - UGN-103 and UGN-104 are in development for broader applications in bladder cancer [48][51] - UGN-501, an oncolytic virus, is being explored for potential use in other cancers beyond urothelial [52] - **Long-term Strategy**: UroGen aims to diversify its portfolio while maintaining a focus on urothelial and specialty cancers [52] Financial Guidance - **Revenue Guidance**: UroGen is not providing specific revenue guidance for the upcoming year but is confident in continued growth based on current trends [39][63] Summary of Key Metrics - **ZUSDURI Market Size**: 60,000 patients, with a potential peak sales of $1.2 billion at 20% market share [37] - **Jelmyto Growth**: Continued single-digit growth, with increased physician engagement [55] This summary encapsulates the key points discussed during the UroGen Pharma conference call, highlighting the company's innovative approach to treating urothelial cancers and its strategic market positioning.

Company Overview - Wildcat Capital Management sold all 495,606 shares of UroGen Pharma Ltd. (NASDAQ:URGN), marking a complete exit from the position valued at approximately $6.79 million [2][3][7] - UroGen Pharma's shares are currently priced at $23.52, reflecting a 113% increase over the past year, significantly outperforming the S&P 500, which rose about 15% in the same timeframe [4] - The company's market capitalization stands at $1.10 billion, with a trailing twelve months (TTM) revenue of $96.52 million and a TTM net income of -$164.64 million [5] Company Operations - UroGen Pharma specializes in developing and commercializing proprietary therapies for urothelial and specialty cancers, utilizing RTGel technology to enhance drug delivery [9][10] - The company targets healthcare providers treating patients with urothelial diseases, particularly focusing on non-muscle invasive bladder and upper tract cancers [10][11] - UroGen's product pipeline and commercial offerings position it as a differentiated player in the specialty pharmaceutical sector, addressing significant unmet medical needs in urothelial oncology [11] Investment Context - The liquidation of UroGen shares by Wildcat Capital is viewed as disciplined capital recycling rather than a lack of confidence, especially given the significant one-year price increase [12][13] - UroGen's commercial product, Jelmyto, remains a key asset, and the company continues to pursue large unmet needs in urothelial cancers [14]

UroGen Pharma FY Conference Summary Company Overview - UroGen Pharma focuses on delivering local medicine to the urothelium, addressing unmet needs in treating urothelial cancers with its innovative RT Gel technology, which transforms from liquid to gel at body temperature [6][7] Key Product: ZUSDURI - ZUSDURI is the first FDA-approved non-surgical option for intermediate-risk non-muscle-invasive bladder cancer (NMIBC) [8] - The product addresses a significant unmet need in treating low-grade, intermediate-risk NMIBC, which has a high recurrence rate [9][10] - Historical treatment involved TURBT procedures, which are invasive and not comprehensive [10][11] Commercial Launch Insights - The commercialization of ZUSDURI is complex, akin to a drug-device combination, requiring operational logistics and physician education [12][13] - The transition from patient enrollment to actual dosing can take up to 60 days, presenting a challenge in revenue recognition [15][17] - Initial sales figures indicated a slower start, but there is optimism about future growth as logistical hurdles are addressed [23][25] Reimbursement Dynamics - Revenue is recognized upon shipment, with a just-in-time inventory model [17][18] - The introduction of a permanent J-code in January is expected to enhance reimbursement confidence among physicians [19][21] - A service warranty is offered to assist physicians with reimbursement processes, although actual usage is anticipated to be low due to positive reimbursement experiences [20] Market Expectations - Approximately 70% of physicians are reportedly waiting for the J-code before using ZUSDURI [21] - Anticipated revenue growth post-J-code is expected to mirror previous experiences with similar products, with a projected 220% increase in revenue within six months [26][27] Competitive Landscape - The entry of competitors into the intermediate-risk space is viewed positively, as it can drive innovation and provide more options for patients [33][34] - UroGen's treatment offers a significant advantage with an 80% complete response rate without the need for surgery, compared to competitors that require surgical intervention [35] Future Developments - UGN-103 and UGN-104 are next-generation formulations with patent protection until 2041, aimed at replacing UGN-102 post-J-code [40][42] - The company is confident in its ability to transition from UGN-102 to UGN-103 without regulatory issues [48][50] Long-term Outlook - The company anticipates continued growth for Jelmyto, its first approved product, as awareness increases with the launch of UGN-102 [51] - 2026 is expected to be a pivotal year for UroGen, with the first two quarters crucial for demonstrating market potential [53]

UroGen Pharma FY Conference Summary Company Overview - **Company**: UroGen Pharma (NasdaqGM:URGN) - **Technology**: RTGel technology, a unique polymer combination that forms a soft gel at body temperature, facilitating drug delivery to the bladder and upper urinary tract [2][3] Core Product Insights - **Product**: Jelmyto, approved for bladder cancer treatment - **Market Opportunity**: Approximately 60,000 patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC) [4] - **Unmet Medical Need**: High recurrence rates among patients, with 23% experiencing five or more recurrences and 68% having two or more [4] Market Dynamics - **Patient Population**: Focus on low-grade disease, which is highly recurrent but not life-threatening [6][7] - **Surgical Failures**: Current treatments often lead to repetitive surgeries, highlighting the need for effective non-surgical options [4][6] Launch and Sales Strategy - **Sales Force Expansion**: Increased from 40 to 82 representatives to support the launch of UGN-102, with a focus on clinical nurse educators [10][11] - **Reimbursement Challenges**: Identified as the biggest barrier to adoption; efforts are in place to address this with field reimbursement teams [10][11][19] Early Launch Metrics - **Revenue Performance**: $1.8 million in Q3 and $4.5 million in October, indicating strong early adoption [14][15] - **Patient Enrollment Forms**: Early indicators of demand are on par with Jelmyto's performance after five years, suggesting a strong market interest [15][16] Future Growth Potential - **J Code Impact**: Anticipated positive effects on revenue post-J code implementation in January 2026, with expectations of increased physician confidence and reimbursement facilitation [18][19] - **Market Penetration**: Projected peak market penetration of over $1 billion, with a conservative estimate of 20% market share [22] Competitive Landscape - **First-Mover Advantage**: UroGen Pharma is positioned as a primary therapy for low-grade intermediate-risk bladder cancer, differentiating from competitors that require surgery [24][25] - **Future Products**: Competitors like J&J and CG are developing adjuvant therapies, which may follow surgical interventions, contrasting with UroGen's non-surgical approach [25][26] Pipeline Developments - **UGN-103**: A new formulation of mitomycin with improved production efficiency, expected to file for NDA in the second half of 2026 [30][31] - **UGN-104**: Successor product for Jelmyto, anticipated to follow UGN-103 by about a year [34] - **Oncolytic Virus (501)**: Currently in IND enabling studies, with potential applications beyond bladder cancer [35][36] Commercial Synergies - **Cross-Promotion**: Increased commercial efforts around UGN-102 are expected to drive growth for Jelmyto, as physicians become more familiar with both products [38] Conclusion UroGen Pharma is strategically positioned in the bladder cancer treatment market with innovative technology and a strong pipeline. The company is addressing significant unmet needs in patient care while navigating challenges related to reimbursement and market adoption. The anticipated impact of the J code and the first-mover advantage in the low-grade intermediate-risk segment are expected to drive future growth.

UroGen Pharma (URGN) Conference Call Summary Company Overview - **Company**: UroGen Pharma Ltd. - **Focus**: Development and commercialization of treatments for urothelial cancers, specifically bladder cancer Key Products - **Jelmyto**: Approved for low-grade upper tract urothelial carcinoma - **Market Size**: 7,000 new patients annually in the U.S., with 3,500 historically undergoing kidney removal - **Sales Projection**: Expected to reach $94 to $98 million in 2025, with a potential peak around $150 million [20][21][22] - **Zosduri (UGN-102)**: Targeting low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) - **Market Size**: 80,000 new bladder cancer patients annually, with 60,000 having recurrent low-grade, intermediate-risk disease - **Revenue Potential**: Estimated at $1 billion plus, with a target of capturing 20% of the market [41][42] Core Technology - **RTGel**: A reverse-thermal hydrogel technology that allows drugs to remain in the bladder for extended periods, enhancing treatment efficacy for urothelial cancers [10][11] Clinical Data - **Jelmyto**: High complete response rates with minimal morbidity, offering a less invasive alternative to kidney removal [12][13] - **Zosduri**: - 80% complete response rate in clinical trials, with durability data showing 72% effectiveness at two years [33][34] - Positioned as a primary therapy, distinct from other adjuvant therapies in development [33] Competitive Landscape - **Current Competitors**: Other companies are developing treatments for high-grade bladder cancer but not yet in the intermediate-risk space [35][36] - **Future Competition**: Anticipated as more products enter the market targeting similar patient populations [36] Commercialization Strategy - **J-Code Importance**: Critical for reimbursement and adoption in urology practices, expected to be established by January 1 [44][45] - **Sales Team Expansion**: Increased from 52 to 82 representatives to enhance market presence and support [62] Financial Position - **Cash Reserves**: Ended Q2 with $162 million, sufficient to reach profitability without immediate capital raising [68][69] - **Debt**: $125 million in debt with Pharmakon, indicating a manageable financial structure [69] Future Outlook - **Growth Potential**: Total addressable market for bladder cancer treatments estimated at over $5 billion, with significant opportunities for both Jelmyto and Zosduri [41][42] - **Long-term Strategy**: Plans to expand into other urothelial cancers and explore additional business development opportunities [64][66] Additional Insights - **Patient Preference**: 90% of patients preferred non-surgical Zosduri treatment over traditional TURBT procedures, indicating strong market demand [38] - **Operational Readiness**: Focus on activating sites and training staff to ensure smooth drug rollout post-J-code [52][53] This summary encapsulates the key points discussed during the UroGen Pharma conference call, highlighting the company's strategic direction, product offerings, and market potential.

Financial Data and Key Metrics Changes - The company expects revenues for the product Almighta to be between $94 million and $98 million for the year, indicating year-over-year growth [62] - The peak potential for the XaStorY opportunity is projected to exceed $1 billion, suggesting a clear path to profitability over the next five years [63] Business Line Data and Key Metrics Changes - The total addressable market (TAM) for low-grade intermediate risk non-muscle invasive bladder cancer is over $5 billion, significantly larger than the $700 million TAM for low-grade upper tract urothelial carcinoma [14] - The company reported that 80% of patients achieved a complete response without undergoing TURBT, with 72% remaining recurrence-free at 24 months [23] Market Data and Key Metrics Changes - The company has expanded its sales force to cover 8,500 physicians, targeting 85% to 90% of the market opportunity, with an initial focus on 2,000 physicians more inclined to adopt new products [36][38] - The company anticipates that 70% of utilization will eventually occur in community settings, despite initial usage being more concentrated in hospital settings [36] Company Strategy and Development Direction - The company is focused on lifecycle management, with plans to transition to UGN-one 103, which has a patent extension until December 2041, and aims to target high-grade disease [71][72] - The company is also exploring collaborations to enhance the efficacy of other drugs using its gel technology, indicating a strategy for broader market penetration [88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming permanent J code expected in January, which is anticipated to accelerate adoption and utilization of their products [44][56] - The management team noted that logistical and reimbursement barriers, rather than clinical concerns, are the primary challenges facing adoption in the urology market [46] Other Important Information - The company is conducting a study on UGN-one 103, with expectations for similar efficacy data to the existing product, and plans to file for approval in 2026 [70][81] - The company is also developing UGN-five 01, an oncolytic virus, with plans to expand its application beyond bladder cancer in the future [89] Q&A Session Summary Question: What is the importance of the J code? - The J code is crucial for urologists as it allows for electronic reimbursement processes, reducing administrative burdens and increasing confidence in product adoption [39][42] Question: How does the company plan to reach community practices? - The company has expanded its sales force and is focusing on a subset of physicians more likely to adopt new products, with a strategy to increase community practice engagement over time [36][38] Question: What is the expectation for breaking even based on the story? - The company has not provided specific guidance on the timeline to breakeven but believes its current cash runway supports a path to profitability given the size of the XaStorY opportunity [62][63]